AUTONOMIX MEDICAL INC (AMIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$4.57-0.22%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — maintain Nasdaq listing standards: stock $4.57 vs $1.00 target; no delisting notice.
Autonomix is developing new medical devices for nerve disorders. The company raised funds in private placements in 2025. Analysts expect losses to shrink from -$34.12 to -$22.68 EPS in 2027. The selloff price drop is not due to bad news. This shows some recovery potential.
The company is still losing money with no revenue. Nasdaq sent a delisting warning in January 2026. The stock fell 25% from its high. Analysts expect losses to continue through 2028. The business may fail to turn profitable.
The market prices in ongoing losses and delisting risk. Our view sees some recovery but remains cautious on profitability timing.
Breaks if: failure to raise capital triggers delisting risk
Breaks if: EPS loss does not improve beyond -34.12 USD per share by FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation. AMIX is currently loss-making and faces high risk, but it has made strides in managing its capital and reducing operating losses.
The market seems to have priced in a cautious outlook, given the company's recent financial performance and high risk. Expectations may be tempered due to the company's losses and the potential for further volatility in the healthcare sector.
Management is actively working on capital allocation and reducing cash burn, which shows some improvement in operating losses. However, the company remains in a loss-making position, and cash from operations is still negative.
The long-term thesis hinges on external factors, such as the performance of sector bellwethers like ABT, MDT, and SYK. If these companies continue to perform well, it could provide a favorable backdrop for AMIX.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Nasdaq delists the company or issues new deficiency notices
In the next 1 to 3 years, AMIX's trajectory will depend on its ability to manage losses and the overall health of the healthcare sector. Not investment advice.